Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD4-positive, alpha-beta T cell | 4 studies | 81% ± 30% | |
T cell | 4 studies | 55% ± 30% | |
macrophage | 4 studies | 79% ± 24% | |
microglial cell | 4 studies | 85% ± 10% | |
endothelial cell | 3 studies | 75% ± 21% | |
fibroblast | 3 studies | 76% ± 28% | |
pericyte | 3 studies | 80% ± 22% | |
B cell | 3 studies | 74% ± 36% | |
astrocyte | 3 studies | 67% ± 29% | |
oligodendrocyte | 3 studies | 65% ± 25% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 783792.59 | 2637 / 2642 | 100% | 8544.83 | 704 / 705 |
kidney | 99% | 382680.49 | 88 / 89 | 98% | 5413.89 | 886 / 901 |
adrenal gland | 97% | 204560.05 | 249 / 258 | 100% | 7478.01 | 230 / 230 |
stomach | 73% | 85774.67 | 262 / 359 | 99% | 4594.78 | 283 / 286 |
liver | 73% | 106800.71 | 164 / 226 | 99% | 3877.08 | 402 / 406 |
esophagus | 60% | 67388.01 | 870 / 1445 | 100% | 4052.18 | 183 / 183 |
intestine | 61% | 68054.50 | 587 / 966 | 98% | 3678.51 | 514 / 527 |
prostate | 49% | 56055.71 | 121 / 245 | 99% | 3772.82 | 498 / 502 |
skin | 48% | 47603.42 | 873 / 1809 | 90% | 2851.56 | 423 / 472 |
breast | 39% | 34400.90 | 177 / 459 | 97% | 3841.39 | 1086 / 1118 |
bladder | 38% | 35471.62 | 8 / 21 | 95% | 3855.55 | 477 / 504 |
thymus | 17% | 15231.38 | 114 / 653 | 96% | 3469.14 | 579 / 605 |
lung | 14% | 11262.58 | 83 / 578 | 90% | 2579.59 | 1035 / 1155 |
pancreas | 4% | 4252.52 | 14 / 328 | 99% | 3320.59 | 177 / 178 |
ovary | 2% | 1783.14 | 4 / 180 | 100% | 8340.61 | 430 / 430 |
eye | 0% | 0 | 0 / 0 | 100% | 4912.17 | 80 / 80 |
ureter | 0% | 0 | 0 / 0 | 100% | 4028.91 | 1 / 1 |
heart | 99% | 292837.40 | 853 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 2036.83 | 28 / 29 |
uterus | 1% | 718.39 | 2 / 170 | 95% | 2600.87 | 434 / 459 |
tonsil | 0% | 0 | 0 / 0 | 91% | 2040.89 | 41 / 45 |
muscle | 87% | 104721.86 | 698 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 49% | 45943.85 | 459 / 929 | 0% | 0 | 0 / 0 |
adipose | 45% | 40878.81 | 547 / 1204 | 0% | 0 | 0 / 0 |
spleen | 39% | 35770.85 | 94 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 13% | 10406.62 | 171 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032147 | Biological process | activation of protein kinase activity |
GO_0033687 | Biological process | osteoblast proliferation |
GO_0048630 | Biological process | skeletal muscle tissue growth |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0072522 | Biological process | purine-containing compound biosynthetic process |
GO_0043610 | Biological process | regulation of carbohydrate utilization |
GO_0071902 | Biological process | positive regulation of protein serine/threonine kinase activity |
GO_2001145 | Biological process | negative regulation of phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0005615 | Cellular component | extracellular space |
GO_0005739 | Cellular component | mitochondrion |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0140297 | Molecular function | DNA-binding transcription factor binding |
Gene name | MT-RNR1 |
Protein name | Mitochondrial-derived peptide MOTS-c (Mitochondrial open reading frame of the 12S rRNA-c) |
Synonyms | |
Description | FUNCTION: Regulates insulin sensitivity and metabolic homeostasis . Inhibits the folate cycle, thereby reducing de novo purine biosynthesis which leads to the accumulation of the de novo purine synthesis intermediate 5-aminoimidazole-4-carboxamide (AICAR) and the activation of the metabolic regulator 5'-AMP-activated protein kinase (AMPK) . Protects against age-dependent and diet-induced insulin resistance as well as diet-induced obesity . In response to metabolic stress, translocates to the nucleus where it binds to antioxidant response elements (ARE) present in the promoter regions of a number of genes and plays a role in regulating nuclear gene expression in an NFE2L2-dependent manner and increasing cellular resistance to metabolic stress . Increases mitochondrial respiration and levels of CPT1A and cytokines IL1B, IL6, IL8, IL10 and TNF in senescent cells . Increases activity of the serine/threonine protein kinase complex mTORC2 and reduces activity of the PTEN phosphatase, thus promoting phosphorylation of AKT . This promotes AKT-mediated phosphorylation of transcription factor FOXO1 which reduces FOXO1 activity, leading to reduced levels of MSTN and promotion of skeletal muscle growth . Promotes osteogenic differentiation of bone marrow mesenchymal stem cells via the TGFB/SMAD pathway . Promotes osteoblast proliferation and osteoblast synthesis of type I collagens COL1A1 and COL1A2 via the TGFB/SMAD pathway . . |
Accessions | A0A0C5B5G6 |